Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

Hepatology

Volumn 67, Issue 4, 2018, Pages 1253-1260

  Poordad, Fred ^a   Pol, Stanislas ^b   Asatryan, Armen ^c   Buti, Maria ^d   Shaw, David ^e   Hézode, Christophe ^f   Felizarta, Franco ^g   Reindollar, Robert W ^h   Gordon, Stuart C ⁱ   Pianko, Stephen ^j   Fried, Michael W ^k   Bernstein, David E ^l   Gallant, Joel ^m   Lin, Chih Wei ^c   Lei, Yang ^c   Ng, Teresa I ^c   Krishnan, Preethi ^c   Kopecky Bromberg, Sarah ^c   Kort, Jens ^c   Mensa, Federico J ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Groupe Hospitalier Cochin Saint Vincent De Paul ^*  (France)

^c ABBVIE INC   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f HENRI MONDOR HOSPITAL   (France)

^g Private Practice   (United States)

^h Piedmont Healthcare Carolinas Center for Liver Disease   (United States)

ⁱ HENRY FORD HEALTH SYSTEM   (United States)

^j SOUTHERN HEALTH   (Australia)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^m Southwest CARE Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; GLECAPREVIR PLUS PIBRENTASVIR; HEPACIVIRIN INHIBITOR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ABT-493; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; PIBRENTASVIR; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BACKACHE; CHRONIC HEPATITIS C; CHRONOPHARMACOLOGY; CLINICAL EVALUATION; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL INFECTION; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INFECTION; WOUND INFECTION; CLINICAL TRIAL; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85041194115     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29671     Document Type: Article

References (22)

1. Jacobson IM, Asante-Appiah E, Wong P, Black TA, Howe AY, Wahl J, et al. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Hepatology 2015;62(Suppl 6):1393A-1394A.
2. Lawitz E, Flamm S, Yang JC, Pang PS, Zhu Y, Svarovskaia E, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol 2015;62(Suppl 2):S192.
3. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1-13.
4. Dvory-Sobol H, Wyles D, Ouyang W, Chodavarapu K, McNally J, Cheng W, et al. Long-term persistance of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 2015;62(Suppl 2):S221.
5. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A, and NS5B with paritaprevir/r-, ombitasvir-, and dasabuvir-based regimens. J Hepatol 2015;62(Suppl 2):S220.
6. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. 2017. http://www.hcvguidelines.org. Accessed July 16, 2017.
7. European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66:153-194.
8. Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clin Infect Dis 2016;62:32-36.
9. Gane E, Shiffman ML, Etzkorn K, Morelli G, Stedman CA, Davis MN, et al. Sofosbuvir/Velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens: results of the GS-US-342-1553 study. J Hepatol 2016;64(Suppl 2):S147-S148.
10. Lawitz E, Poordad F, Gutierrez JA, Wells JT, Landaverde CE, Reiling JR, et al. C-SWIFT Retreatment (Part B): 12 Weeks of Elbasvir/Grazoprevir with Sofosbuvir and Ribavirin Successfully Treated G1-Infected Subjects who Failed Short-Duration All-Oral Therapy. Paper presented at The Liver Meeting 2015: American Association for the Study of Liver Diseases (AASLD) 2015, November 13-17, San Francisco, CA.
11. Poordad F, Bennett M, Sepe TE, Cohen E, Reindollar RW, Everson GT, et al. QUARTZ-I: Retreatment of HCV Genotype 1 DAA-failures With Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir. Paper presented at The Liver Meeting 2015: American Association for the Study of Liver Diseases (AASLD) 2015, November 13-17, San Francisco, CA.
12. Hezode C, Fourati S, Chevaliez S, Scoazec G, Soulier A, Varaut A, et al. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C. Clin Infect Dis 2017;64:1615-1618.
13. VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) [package insert]. Foster City, CA: Gilead Sciences; 2017.
14. Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med 2017;376:2134-2146.
15. SOVALDI (sofosbuvir) tablets [package insert]. Foster City, CA: Gilead Sciences. Revised on November 2017.
16. Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015;7:6716-6729.
17. Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, et al. ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotype coverage. 2014. http://www.croiconference.org/sites/default/files/posters/636.pdf. Accessed July 25, 2016.
18. Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 2017;61. pii: e02558-16. doi: 10.1128/AAC.02558-16. Print 2017 May.
19. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3:514-520.
20. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017;66:389-397.
21. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-1192.
22. Pilot-Matias T, Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, et al. Resistance Analysis in the MAGELLAN-I Study (Part 2): Glecaprevir/Pibrentasvir Therapy in HCV-Infected Patients who had Failed Prior DAA Regimens Containing NS3/4A Protease and/or NS5A Inhibitors (SAT-204). Paper presented at International Liver Congress (EASL) 2017, April 19-23, Amsterdam, The Netherlands.